Latest Drug delivery Stories
BETHLEHEM, Pa., June 6, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has added new coating capabilities for preparing polymer film-based drug products from liquid formulations, under cGMPs. According to Garry Gwozdz, Director, Formulation Services, "Particle Sciences' purpose is to provide our clients with the most efficient drug product. Increasingly, we are seeing a demand for thin film-based products, particularly with respect to transdermal drug-eluting...
FARMINGTON, Conn., May 30, 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased to announce the immediate availability of two new market research reports from Greystone Research Associates examining the markets for Transmucosal Drug Delivery and Systemic Nasal Sprays. (Photo: http://photos.prnewswire.com/prnh/20120530/CG15754) Oral Transmucosal Drug Delivery MarketGreystone Research Associates' new market study "Oral Transmucosal Drug Delivery: Products, Players, Markets...
ORANGE COUNTY, Calif., May 24, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc., a California corporation developing a novel drug-delivery platform for cancer pharmaceuticals, announced today that the company has added Dr. Paul Glidden as Vice President of Research and Development. "Dr. Glidden has worked for over 20 years developing new chemical and molecular entities leading to over a dozen commercialized pharmaceuticals," said Dr. Smith. "His...
MOUNT OLIVE, N.J., May 24, 2012 /PRNewswire/ -- Flowonix Medical Incorporated, a medical device company focused on providing advanced implantable drug delivery solutions, announced today that it has raised $25 million in new financing. Led by RFT Investment Company, LLC, an Atlanta-based private investment institution, this new funding will enable Flowonix to enter the U.S. market as well as continue its development of leading-edge drug delivery technologies. The launch of its...
BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV. TIDES 2012 is the premier conference focused on...
DALLAS and NEW YORK, May 17, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program. The investor conference call...
MALVERN, Pa., May 17, 2012 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today Bob Radie, president and chief executive officer (CEO), will present at the Life Sciences Europe conference on May 23 organized by the International Venture Club. Mr. Radie will review the company's patented technology and pipeline of abuse-deterrent opioids that are nearing phase 3....
In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...
REDWOOD CITY, Calif., May 14, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA). PT003 and its components, PT001 (GP MDI) and PT005 (FF MDI) are being developed...
A major breakthrough in the quest for oral insulin was announced by Dr. Daniel DeBrouse, CEO, CSO of Tamarisk Technologies of Meeker, OK. This comes just days after his publishing of nearly a decade of research in oral drug delivery. Tamarisk Technologies is already in licensing talks with several big pharmas. Meeker, OK (PRWEB) May 09, 2012 "The data doesn't lie," said Dr DeBrouse. "After years of research, I am happy to say, not only have we achieved our goal of providing the world with...
